The pioneering charity Prostate Cancer Research convened industry leaders, NHS experts and patients for a webinar exploring how artificial intelligence (AI) is transforming prostate cancer imaging and clinical pathways. The session provided valuable insights for healthcare professionals seeking innovative approaches to address late diagnosis and reduce unnecessary prostate biopsies.
Two companies showcased their AI-powered imaging solutions: Quibim, based in Spain, and UK-based Lucida Medical.
Quibim presented updates on its QP Prostate® software, currently being trialled across seven NHS centres. The MRI solution aims to enhance image quality and support more informed treatment decisions.
Lucida Medical demonstrated its Pi™ technology, now deployed in up to 15 UK hospitals. Lucida supports MRI enhancement, biopsy prioritisation, and fusion biopsy planning. Clinical studies show that Pi™ improves diagnostic accuracy, reduces inter-reader variability among radiologists, and shortens the time to biopsy.
The webinar highlighted the growing role of AI in prostate MRI, emphasising its potential to support radiologists, improve consistency, streamline workflows, and ultimately enhance patient outcomes.
Patient representative Jason Curtis shared his personal experience of prostate cancer diagnosis, describing the anxiety caused by inconsistencies in staging and treatment decisions. He praised AI’s potential to deliver faster, more accurate results, reduce uncertainty, and improve patients’ emotional wellbeing.
The session concluded with contributions from the NHS InSites team. A peer network of 18 NHS organisations focused on accelerating the adoption of healthcare innovations. The InSites programme enables organisations to share learning and support the implementation of new technologies.
Understanding the challenges and opportunities of AI can be complex. PCR is committed to creating opportunities for healthcare professionals to engage with more company founders, understand new technologies, gain confidence in the supporting evidence, and understand the real-world benefits.
Learn more about the latest advances in AI for prostate cancer imaging by watching the full webinar and joining the conversation at https://www.theinfopool.co.uk/HCPs.
For further information, contact Susannah Ramsay at sramsay@pcr.org.uk.
Prostate Cancer Research (PCR) is a charity dedicated to advancing prostate cancer research, education and clinical innovation. Their translational arm Proven Connect, partners with companies to accelerate innovations that can transform prostate cancer diagnosis and treatment.
https://www.prostate-cancer-research.org.uk/
https://quibim.com/
https://lucidamedical.com/
https://nhscep.com/insites-programme/
